Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiaamlacuteto startingdiagnosis of
  Phrases that lowered it: lymphomamalehcvstempatient
• Sponsor's past termination rate: 12.8% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Maximum age: 100 (lowers risk) · Who can join
• Keywords listed: 27 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 18.2% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 307 (raises risk) · Sponsor's track record
• Sponsor's past trials: 549 (raises risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers NCT01497392 · started 2012 · scored riskier than 68% of active trials completed
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems NCT03814005 · started 2019 · scored riskier than 33% of active trials completed
• Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) NCT02319369 · started 2014 · scored riskier than 59% of active trials terminated
• VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) NCT04702425 · started 2021 · scored riskier than 66% of active trials terminated
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia NCT04207190 · started 2020 · scored riskier than 80% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.